Related Experiment Video
Updated: Mar 10, 2026
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
Published on: April 4, 2019
Pharmacist-driven respiratory syncytial virus prophylaxis stewardship service in a neonatal intensive care unit
Sara E Rostas1, Christopher McPherson2
1Department of Pharmacy, Brigham and Women's Hospital, Boston, MA. srostas@partners.org.
Purpose:
The development and implementation of a pharmacist-driven respiratory syncytial virus (RSV) prophylaxis stewardship program in a neonatal intensive care unit (NICU) are described.
Summary:
An RSV prophylaxis stewardship service was created in the NICU at Brigham and Women's Hospital to align with the newly updated 2014 American Academy of Pediatrics (AAP) recommendations for palivizumab. The service comprised two NICU clinical pharmacists with oversight from the NICU medical director and the chair of the NICU infection control committee. Supervising physicians provided oversight for the identification of qualified patients on a weekly basis and assisted in the evaluation of controversial cases. The goals of the RSV prophylaxis stewardship service were to identify qualifying infants, improve adherence to the current AAP recommendations, educate staff and families on the recently updated AAP recommendations, streamline communication between providers regarding qualifying infants, and prepare and deliver palivizumab for administration in an organized and cost-effective manner. Twice-weekly "RSV prophylaxis days" were designated, with a set administration time on each day. Workflow was successfully streamlined between members of the healthcare team, including NICU pharmacists, prescribers, off-shift pharmacists, and nurses.
Conclusion:
Pharmacists involved in a multidisciplinary RSV prophylaxis stewardship service successfully identified qualifying patients for RSV prophylaxis while adhering to the latest AAP recommendations, educated staff and families regarding RSV, streamlined communication among healthcare providers, and ensured preparation of palivizumab in an organized and cost-effective manner.
More Related Videos
09:14An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
09:01An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:23Acute Respiratory Failure-IV
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:21Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...